Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment

Study summary

This pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within Veterans Health Administration.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedUnsigned note to provider about cessation medication prescription and Proactive Telephone Counseling from VA Quitline

The study team can explain what participation involves.

Who it may be forSmoking Reduction · Tobacco Use

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 8, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?VA Office of Research and Development

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: VA Office of Research and Development
Interventions being studied: Behavioral: Unsigned note to provider about cessation medication prescription; Behavioral: Proactive Telephone Counseling from VA Quitline

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Providers who schedule patients for a lung cancer screening at either of the two VA sites.
Patients who participate in lung cancer screening and are current smokers at the time of scheduling their screening exam.

Reasons someone may not be able to joinExclusion criteria

Providers who currently systematically prescribe cessation support medication to all current smokers will be excluded.
Patients with urgent findings requiring biopsy/immediate attention on the screening CT will be excluded.
Patients with a prior diagnosis of lung cancer or who are receiving active therapy for any cancer, except skin cancer, will be excluded.
Patients previously diagnosed with cognitive impairment, dementia, or severe behavioral disorders, or have an indication in chart review of difficulty communicating or participating in telephone counseling sessions will be excluded.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Manhattan Campus of the VA NY Harbor Healthcare System, New York, NYNew York, New York
Providence VA Medical Center, Providence, RIProvidence, Rhode Island
VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, Washington

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 8, 2024. Always confirm current availability with the study team.

View original record ↗